SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (12099)1/7/2019 11:47:08 AM
From: bmaz001  Respond to of 12215
 
Maybe SRPT is down 5% because management released that weird 8-K. :-)

I'm still kicking myself for unloading SAGE at $63 back in 9/17. I'll have to check my notes to figure out what I was thinking.



To: scaram(o)uche who wrote (12099)1/7/2019 1:06:46 PM
From: tuck1 Recommendation

Recommended By
scaram(o)uche

  Respond to of 12215
 
SRPT: several moving parts today. Guidance only in-line with consensus. FDA applying mfg guidelines to SRPT that was same for ABEO, but perhaps unexpected (need for clinical data from commercial product for filing), and no update on newer drug. Might create a buying op if the general market takes a quick breather, but I don't really follow the stock; here just aggregating tweeted info.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News